📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
NEUTRAL
score: 0.40
SENTIMENT
BULLISH
TOTAL VIEWS
74
MDT Latest News & AI Sentiment Analysis
5 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 14 ARTICLES
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed (OBIO) released Q2 2026 earnings with updates on two pivotal clinical programs: BACKBEAT and Virtue trials. The...
Is Medtronic (MDT) Becoming a Turnaround Story?
Medtronic (MDT) received an upgrade to Buy from UBS, marking a shift in institutional sentiment toward the medical device manufacturer....
Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech
ISRG maintains competitive positioning in surgical robotics despite intensifying market competition. The article frames the company's...
Jury Says Medtronic Owes $88 Million in First Trial Over Covidien’s Hernia Mesh
Medtronic (MDT) faces significant litigation risk after a federal jury awarded $88 million in the first trial outcome related to...
Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone
Johnson & Johnson (JNJ) received positive commentary from analyst Jim Cramer following what the market perceives as a meaningful...
Intuitive Surgical down as J&J wins FDA nod for surgical robot
JNJ's FDA clearance of the Ottava surgical robot represents a significant competitive inflection point in the minimally invasive surgery...
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
ViCentra, a European medical device innovator focused on insulin delivery systems, has appointed Ian Wells as Chief Financial Officer...
Medtronic: Undervalued, And The Tailwinds Are Just Getting Started (NYSE:MDT)
Medtronic (MDT) is positioned as an undervalued healthcare equipment manufacturer with structural growth catalysts ahead. The thesis...
Medtronic Stock: Guidance Built To Be Beaten - Buy (NYSE:MDT)
Medtronic (MDT) reported $36.4B in revenue representing its strongest growth trajectory in a decade, driven primarily by strength in...
Medtronic: A Near Decade High Dividend For This Aristocrat (NYSE:MDT)
Medtronic (MDT) is being highlighted for its dividend aristocrat status combined with elevated yield levels not seen in approximately a...
Medtronic: Coming Back, But Not Yet Ready For Greatness (NYSE:MDT)
Medtronic (MDT) exhibits a fundamental paradox: robust asset quality combined with strategic execution challenges and anemic organic...
3 Stocks I'm Not Selling No Matter What the Market Does
This opinion-driven commentary emphasizes a long-term equity holding strategy centered on fundamental business quality and dividend...
10 Best Long Term Stocks to Buy According to Hedge Funds
This article represents a curated listicle of hedge fund holdings rather than breaking market news or a significant catalyst. The...
Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years
Medtronic (MDT) is positioned as a long-duration defensive holding for investors seeking stable, predictable returns rather than growth...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice